RANDOMIZED CLINICAL STUDY OF HAPLO-IDENTICAL DONORS VERSUS UNRELATED DONORS
- Registry ID
- HAPLO VS. URD IN AML
- Source registry
- HEALTH_CANADA
- Status
- Closed
- Study type
- INTERVENTIONAL
- Sponsor
- PRINCESS MARGARET CANCER CENTRE
- Start date
- 2020-12-04
- Completion date
- 2023-03-29
- Last update
- 2019-08-23
Conditions
- ACUTE MYELOID LEUKEMIA
- HEMATOPOIETIC STEM CELL TRANSPLANT
Related clinical trials
- PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ASSESSING
ZIFTOMENIB IN COMBINATION WITH EITHER STANDARD OF CARE NONINTENSIVE
(VENETOCLAX+AZACITIDINE) OR INTENSIVE (7+3) THERAPY IN PATIENTS WITH
UNTREATED NPM1 MUTATED OR KMT2A REARRANGED ACUTE MYELOID LEUKEMIA
- A PHASE 1 STUDY OF TAK-243 FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA OR MYELODYSPLASTIC SYNDROMES WITH INCREASED BLASTS
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF
BLEXIMENIB, VENETOCLAX AND AZACITIDINE FOR THE TREATMENT OF
PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
HARBORING KMT2A REARRANGEMENTS OR NPM1 MUTATIONS WHO ARE
INELIGIBLE FOR INTENSIVE CHEMOTHERAPY
- A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF QUIZARTINIB
ADMINISTERED IN COMBINATION WITH INDUCTION AND CONSOLIDATION CHEMOTHERAPY
AND ADMINISTERED AS MAINTENANCE THERAPY IN ADULT PATIENTS WITH NEWLY
DIAGNOSED FLT3-ITD NEGATIVE ACUTE MYELOID LEUKEMIA (QUANTUM-WILD)
- A PHASE 1, FIRST IN HUMAN, DOSE ESCALATION STUDY OF JNJ-
89853413 FOR RELAPSED OR REFRACTORY ACUTE MYELOID
LEUKEMIA OR MYELODYPLASTIC NEOPLASMS
- A PHASE 1, OPEN-LABEL, DOSE-ESCALATION, AND DOSE-EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF REVUMENIB IN COMBINATION WITH INTENSIVE CHEMOTHERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIAS HARBORING ALTERATIONS IN LYSINE-SPECIFIC METHYLTRANSFERASE 2A (KMT2A/MLL), NUCLEOPHOSMIN 1 (NPM1), AND NUCLEOPORIN 98 (NUP98) GENES
View on source registry